Cargando…
DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy
BACKGROUND: TIGIT is an immune checkpoint under investigation as therapeutic target. Understanding the regulation of TIGIT on an epigenetic level might support the development of companion biomarkers. METHODS: We correlated TIGIT DNA methylation of single CpG sites with gene expression, signatures o...
Autores principales: | Niebel, Dennis, Fröhlich, Anne, Zarbl, Romina, Fietz, Simon, de Vos, Luka, Vogt, Timo J., Dietrich, Jörn, Sirokay, Judith, Kuster, Pia, Saavedra, Gonzalo, Ramírez Valladolid, Susana, Hoffmann, Friederike, Strieth, Sebastian, Landsberg, Jennifer, Dietrich, Dimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004005/ https://www.ncbi.nlm.nih.gov/pubmed/35410311 http://dx.doi.org/10.1186/s13148-022-01270-2 |
Ejemplares similares
-
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
por: Fröhlich, Anne, et al.
Publicado: (2020) -
Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma
por: Hoffmann, Friederike, et al.
Publicado: (2020) -
Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma
por: Fröhlich, Anne, et al.
Publicado: (2020) -
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020) -
CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma
por: Hoffmann, Friederike, et al.
Publicado: (2023)